Cytomegalovirus-specific T cells - ViraCyte

Drug Profile

Cytomegalovirus-specific T cells - ViraCyte

Alternative Names: CMV-specific T cell therapy - ViraCyte; CMV-specific T cells - ViraCyte; Cytomegalovirus-specific T cell therapy - ViraCyte; HLA-matched Viralym-C cells; Human leukocyte antigen (HLA)-matched CMV-specific T lymphocytes - ViraCyte; Viralym-C

Latest Information Update: 12 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ViraCyte
  • Class T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cytomegalovirus infections

Most Recent Events

  • 11 Jul 2017 Updated efficacy data from a phase I trial in Cytomegalovirus infections released by ViraCyte
  • 11 Jul 2017 ViraCyte completes a phase I trial in Cytomegalovirus infections (In children, In adolescents, In adults) in USA
  • 24 Jan 2017 Cytomegalovirus-specific T cells - ViraCyte receives Orphan Drug status for Cytomegalovirus infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top